Works matching IS 15430790 AND DT 2021 AND VI 19 AND IP 5
Results: 7
Lenalidomide in DLBCL: Are We Past the Cell of Origin?
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 5, p. 320
- By:
- Publication type:
- Article
The Evolving Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 5, p. 305
- By:
- Publication type:
- Article
What's Next for Immunotherapy in Locally Advanced NSCLC?
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 5, p. 302
- By:
- Publication type:
- Article
Chimeric Antigen Receptor T-Cell Therapy Plus Checkpoint Blockade in Thoracic Cancers.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 5, p. 295
- By:
- Publication type:
- Article
The Use of Telemedicine in Hematology and Oncology.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 5, p. 292
- By:
- Publication type:
- Article
Recently Approved Drugs Herald a New Era in Therapy for Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 5, p. 284
- By:
- Publication type:
- Article
The Too-Typical Clinical Conundrum.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 5, p. 272
- By:
- Publication type:
- Article